Search clinical trials for: Pemziviptadil (PB1046)

Total 35 results

PhaseBio Pharmaceuticals Inc.

Terminated

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (VIP Extend)

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Terminated

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (VIP)

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Terminated

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (VANGARD)

Pneumonia | Respiratory Failure | Respiratory Insufficiency | COVID 19 | Acute Respiratory Distress Syndrome | SARS-CoV-2 | Coronavirus | Cytokine Storm | Pulmonary Edema | Cardiac Event | Respiratory Complication | Cardiac Dysfunction | Hypoxemic Respiratory Failure | Hypoxic Respiratory Failure | Cardiac Failure | Cardiac... and other conditions

United States
PhaseBio Pharmaceuticals Inc.

Completed

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

Heart Failure

United States
University of California, Los Angeles

Completed

Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves

Eisenmenger Syndrome

United States
PhaseBio Pharmaceuticals Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

Essential Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Essential Hypertension

United States
Medtronic Heart Valves

Completed

Melody PB1016 Surveillance Study

Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects

Spain, United States, Austria, Canada
GI Biome, Inc.

Recruiting

Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer

Cancer | Colorectal Cancer | Rectal Cancer | Solid Tumor | Sigmoid Colon Cancer | Rectosigmoid Junction Cancer

Korea, Republic of
PhaseBio Pharmaceuticals Inc.

Completed

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

Diabetes Mellitus, Type 2

United States
PhaseBio Pharmaceuticals Inc.

Completed

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Proacta, Incorporated

Unknown

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia

United States
Brigham and Women's Hospital

Completed

Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA

MSA

United States
Proacta, Incorporated

Completed

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand
Brigham and Women's Hospital
Genzyme, a Sanofi Company

Not yet recruiting

Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

Multiple Sclerosis

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (PBR06)

Multiple Sclerosis | Parkinson Disease | Alzheimer Disease

United States
Molecular NeuroImaging

Completed

Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET

Amyotrophic Lateral Sclerosis | Healthy Volunteers

United States
Brigham and Women's Hospital

Recruiting

Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

Synucleinopathies | Neurodegenerative Diseases | Ataxia | sca3 | MSA - Multiple System Atrophy

United States
University Hospital, Bordeaux

Terminated

Molecular Imaging of Inflammation With 18F-PBR06 to Identify Unstable Carotid Plaques in Patients With Stroke (PLAQINSTEP)

Stroke

France
Brigham and Women's Hospital
Biohaven Pharmaceuticals, Inc.

Completed

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

Multiple System Atrophy | Multiple System Atrophy, Parkinson Variant (Disorder) | Multiple System Atrophy, Cerebellar Variant | Multiple System Atrophy (MSA) With Orthostatic Hypotension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Brigham and Women's Hospital
U.S. Army Medical Research Acquisition Activity

Recruiting

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

Multiple Sclerosis

United States
Brigham and Women's Hospital
Novartis

Recruiting

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Multiple Sclerosis

United States
Brigham and Women's Hospital

Unknown

Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease (MAPET)

Multiple Sclerosis | Alzheimer's Disease

United States
Panolos Bioscience

Recruiting

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Gastric Cancer | Solid Tumor | Advanced Solid Tumor | Solid Tumor, Adult

Korea, Republic of
Proacta, Incorporated

Terminated

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Lung Cancer

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Type 2 Diabetes Mellitus

United States
Peking University Third Hospital

Recruiting

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients (FB1006)

Sporadic and Familial Amyotrophic Lateral Sclerosis

China
Shyla Cantor
Sytheon Ltd.

Completed

Effects of 2% IDL Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin

Xerosis Cutis

United States
Proacta, Incorporated

Terminated

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, Taiwan, Singapore, Hong Kong
Hordinsky, Maria K., MD

Completed

Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice

Alopecia

United States
Jagiellonian University

Completed

Probiotic Supplementation in the Term Newborns Delivered by Caesarean Section

Microbiota, Cesarean Section, Probiotics, Dysbiosis
Proacta, Incorporated

Completed

PR104 and G-CSF in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States, New Zealand
Proacta, Incorporated

Terminated

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Canada, New Zealand

3

Subscribe